期刊文献+

IL-26在胃癌中表达及其生物学机制 被引量:2

Expression and biological mechanism of IL-26 in human gastric cancer
原文传递
导出
摘要 目的探讨白细胞介素26(IL-26)在人胃癌中的表达及其生物学机制。方法采用实时荧光定量PCR和免疫组织化学检测60例胃癌组织及相应癌旁组织中IL-26及其受体IL-20R1的表达。采用IL-26 1、10、50ng/ml刺激人胃癌细胞株MKN45后,采用MTT法和流式细胞术分别检测细胞增殖和凋亡能力,Western blot检测转录激活子3(STAT3)信号通路激活情况。结果胃癌组织中IL-26及其受体IL-20R1表达水平高于癌旁组织(P<0.01)。IL-26呈浓度依赖性地促进MKN45细胞增殖及抗凋亡能力,且上调STAT3磷酸化水平、B细胞淋巴瘤-白血病2(Bcl-2)和细胞周期蛋白D1(cyclinD1)蛋白表达(P<0.05)。结论 IL-26在人胃癌组织中高表达,并且通过激活STAT3信号通路,从而促进胃癌细胞的增殖。 Objective To investigate the expression and biological mechanism of interleukin-26 (IL-26) in human gastric cancer. Methods The expressions of IL-26 and IL-20R1 were detected by RFQ-PCR and immunohistochemistry in 60 cases of gastric cancer and tumor-adjacent normal tissues. Human gastric cancer cell line MKN45 was stimulated with IL-26 1,10 and 50 ng/ml, and then cell proliferation and apoptosis were measured by MTT and flowcytometry, respectively. The activation of STAT3 signaling pathway was determined by Western blot. Results The expressions of IL-26 and II;20R1 in gastric cancer tissues were higher than those in tumor-adiacent normal tissues(P〈0.01). IL-26 significantly promoted the proliferation and anti-apoptosis of MKN45 cells in a dose-dependent manner, and upregulated the expressions of STAT3 phosphorylation, Bcl-2 and cyclin D1 (P〈0. 05). Conclusion IL-26 is highly expressed in human gastric cancer and can enhance the proliferation of MKN45 cells via the activation of STAT3 signaling pathway.
出处 《江苏医药》 CAS 2015年第9期1030-1032,共3页 Jiangsu Medical Journal
关键词 胃癌 白细胞介素26 转录激活子3 Gastric cancer Interleukin-26 Signal transducer and activator of transcription 3
  • 相关文献

参考文献8

  • 1Knappe A, HOr S, Wittmann S, et al. Induction of a novel cellular homolog of interleukin 10, AK155, by transformation of T lymphocytes with herpesvirus saimiri[J]. J Virol, 2000,74 (8):3881-3887.
  • 2Conti P, Kempuraj D, Frydas S, et al. II:10 subfamily members: II:19, II:20, IL-22, IL-24 and II:26 [J]. Immunol Lett,2003,88(3) : 171-174.
  • 3Fickenscher H, Pirzer H. lnterleukin-26[J]. Int lmmuno- pharmacol, 2004,4 ( 5 ) : 609-613.
  • 4Sheikh F, Baurin VV, Lewis Antes A, et al. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-I 0 receptor 2[j]. J Immunol, 2004,172 (4) : 2006-2010.
  • 5Boniface K, Lecron JC, Bernard FX, et al. Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis o{ psoriasis[J]. Eur Cytokine Netw, 2005,16 (4):309-319.
  • 6Fitzpatrick LR. Novel Pharmacological Approaches for Inflam- matory Bowel Disease: Targeting Key Intracellular Pathways and the II:23/II:17 Axis [J ]. Int J lnflam, 2012, 2012: 389404.
  • 7Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty [J] Immunity, 2012,36 (4) : 503-514.
  • 8Yu H, Pardoll D,Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3 [J]. Nat Rev Cancer, 2009,9( 11 ) : 798-809.

同被引文献16

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部